Arrowhead Pharmaceuticals, Inc. ARWR Stock Forecast
AI-powered price prediction and analysis for Arrowhead Pharmaceuticals, Inc. · Alpha · vs marketSwitch to Total
See ARWR's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry.
Latest News
Where ARWR sits on the market map
Pharmaceutical Preparations Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. | $6.96B | – | |
| LLY Eli Lilly & Co | $1.33T | 45.8x | |
| JNJ Johnson & Johnson | $679.13B | 42.9x | |
| ABBV Abbvie Inc. | $518.30B | 44.9x | |
| MRK Merck & Co., Inc. | $367.02B | 153.4x | |
| NVS Novartis Ag | $312.35B | 9.8x | |
| AZN Astrazeneca Plc | $293.55B | 13.7x | |
| ABT Abbott Laboratories | $192.16B | 39.1x | |
| NVO Novo Nordisk A S | $183.89B | 3.1x | |
| PFE Pfizer Inc | $166.60B | 37.0x | |
| VRTX Vertex Pharmaceuticals Inc / … | $139.62B | 35.5x | |
| BMY Bristol Myers Squibb Co | $127.02B | 13.8x | |
| SNY Sanofi | $118.63B | – | |
| GSK Gsk Plc | $103.98B | 5.7x | |
| REGN Regeneron Pharmaceuticals, Inc. | $94.71B | 20.4x | |
| TAK Takeda Pharmaceutical Co Ltd | $65.88B | 6.4x | |
| TEVA Teva Pharmaceutical Industries Ltd | $50.07B | 41.3x | |
| ONC Beone Medicines Ltd. | $47.44B | 1159.3x | |
| GMAB Genmab A/S | $35.90B | 2.2x | |
| ZTS Zoetis Inc. | $32.81B | 13.5x | |
| RPRX Royalty Pharma Plc | $29.45B | 48.1x | |
| ROIV Roivant Sciences Ltd. | $29.38B | – | |
| INSM Insmed Inc | $25.47B | – | |
| UTHR United Therapeutics Corp | $24.11B | 21.2x | |
| VTRS Viatris Inc | $22.87B | – | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.98B | 7.4x | |
| ASND Ascendis Pharma A/S | $17.07B | – | |
| JAZZ Jazz Pharmaceuticals Plc | $15.81B | 80.4x | |
| BBIO Bridgebio Pharma, Inc. | $15.18B | – | |
| SMMT Summit Therapeutics Inc. | $14.23B | – | |
| ELAN Elanco Animal Health Inc | $13.41B | – | |
| RDY Dr Reddys Laboratories Ltd | $12.56B | 16.5x | |
| BMRN Biomarin Pharmaceutical Inc | $11.07B | 571.8x | |
| TGTX Tg Therapeutics, Inc. | $10.06B | 91.9x | |
| MDGL Madrigal Pharmaceuticals, Inc. | $10.00B | – | |
| SYRE Spyre Therapeutics, Inc. | $9.61B | – | |
| PRAX Praxis Precision Medicines, Inc. | $9.30B | – | |
| PTGX Protagonist Therapeutics, Inc | $8.79B | 34.6x | |
| CORT Corcept Therapeutics Inc | $8.11B | 44.9x | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.85B | – | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.76B | 91.5x | |
| ALKS Alkermes Plc. | $7.75B | 44.8x | |
| CYTK Cytokinetics Inc | $7.67B | – | |
| AXSM Axsome Therapeutics, Inc. | $7.02B | – | |
| ORKA Oruka Therapeutics, Inc. | $6.92B | – | |
| ABVX Abivax S.A. | $6.83B | – | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.80B | 141.9x | |
| LGND Ligand Pharmaceuticals Inc | $6.28B | 119.9x | |
| BLTE Belite Bio, Inc | $6.20B | – | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.05B | – | |
| MANE Veradermics, Inc | $6.01B | – | |
| COGT Cogent Biosciences, Inc. | $5.82B | – | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | – | |
| ERAS Erasca, Inc. | $5.46B | – | |
| PTCT Ptc Therapeutics, Inc. | $5.43B | – | |
| EWTX Edgewise Therapeutics, Inc. | $5.29B | 5.8x | |
| IONS Ionis Pharmaceuticals Inc | $5.15B | – | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $5.03B | – | |
| TVTX Travere Therapeutics, Inc. | $4.62B | – | |
| LEGN Legend Biotech Corp | $4.49B | – |
FAQ
Is Arrowhead Pharmaceuticals, Inc. a good stock to buy?
Our AI analyzes Arrowhead Pharmaceuticals, Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Arrowhead Pharmaceuticals, Inc. predictions?
For ARWR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -22.0%, measured on 358 forecast dates between 2022-08-23 and 2026-08-12 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -1.0%, measured on 400 forecast dates between 2022-08-23 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Arrowhead Pharmaceuticals, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 10, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Arrowhead Pharmaceuticals, Inc.? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.